(regadenoson injection)
Drug Interaction
Patients should be instructed to avoid consumption of any products containing methylxanthines, including caffeinated coffee, tea or other caffeinated beverages, caffeine-containing drug products, aminophylline and theophylline for at least 12 hours before a scheduled radionuclide MPI [see Warnings and Precautions (5.8) and Clinical Pharmacology (12.2)].
Cardiovascular
Advise patients that they may be at increased risk of fatal and nonfatal heart attacks, abnormal heart rhythms, cardiac arrest, significant increase or decrease in blood pressure, or cerebrovascular accidents (stroke) with the use of regadenoson injection [see Warnings and Precautions (5.1), (5.3), (5.5), (5.6) and (5.9)].
Hypersensitivity
Inform patients that allergic reactions have been reported with regadenoson injection. Advise patients how to recognize such a reaction and when to seek medical attention [see Warnings and Precautions (5.4)].
Respiratory
Advise patients with COPD or asthma about the need for administration of pre- and post-study bronchodilator therapy and to call their clinician if they experience any shortness of breath or difficulty breathing following an MPI study with regadenoson injection [see Warnings and Precautions (5.7)].
Seizures
Advise patients that they may be at increased risk of seizures. Question patients about a history of seizures [see Warnings and Precautions (5.8)].
Lactation
Advise a woman to pump and discard breast milk for 10 hours after regadenoson injection administration [see Use in Specific Populations (8.2)].
Additional Resources
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.
Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.
Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for a Pfizer medicine or a vaccine.
The submission will be reviewed during our standard business hours.
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.